by
Gus Iversen, Editor in Chief | July 27, 2015
Mallinckrodt's contrast business and Guerbet (as a whole) combined to earn almost $9 billion in 2014 — now they will combine as a single entity.
Guerbet's work council has unanimously issued a favorable opinion of the acquisition. In a statement just released this evening, the company outlined its plans for the agreement in terms of both incentives and future planning.
It cites three core strengths in the contrast media and delivery systems (CMDS) segment of Mallinckrodt.
Ad Statistics
Times Displayed: 46235
Times Visited: 1406 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
1)
An efficient industrial and commercial platform with four production sites in Ireland and in North America, and a global distribution network covering approximately 65 countries
2)
A comprehensive range of delivery systems and imaging solutions for X-ray scanners, X-ray cardiac and vascular imaging, urological imaging and magnetic resonance imaging
3)
A large portfolio of patents and other intellectual property rights
Mallinckrodt's CMDS business is well positioned with Optiray and Optiject/Ultraject, whereas Guerbet holds a similar position in MRI with Dotarem.
Since Guerbet has a stronghold in the European market and Mallinckrodt's CMDS has a similar footing in the U.S., the resulting company expects to be able to leverage those strengths and build their presence in both markets.
The entire $270 million purchase will be paid in cash and is expected to close in the next few months.
